The purpose of this study is to investigate the effects of metformin to prevent frailty in pre-frail non-diabetic elderly. Several outcomes measured in this study are frailty status, quality of life, handgrip strength, gait speed, and serum myostatin levels. We hypothesize that metformin for 16 weeks could prevent frailty in pre-frail elderly.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
150
Metformin tablet 500 mg three times a day for 16 weeks. If there is no significant outcome obtained between two arms in 16 weeks, metformin will continue until 24 weeks.
Placebo three times a day for 16 weeks. If there is no significant outcome obtained between two arms in 16 weeks, placebo will continue until 24 weeks.
Cipto Mangunkusumo General Hospital
Central Jakarta, Jakarta Special Capital Region, Indonesia
RECRUITINGChange from baseline in frailty status at 16 weeks
Measurement: Frailty Index 40 items
Time frame: Baseline and at 16 weeks
Change from baseline in health-related quality of life (HrQoL) at 16 weeks
Measurement: EQ-5D (with permission)
Time frame: Baseline and at 16 weeks
Change from baseline in handgrip strength at 16 weeks
Measurement: handgrip dynamometer (Jamar Hydraulic Hand Dynamometer Model J00105)
Time frame: Baseline and at 16 weeks
Change from baseline in gait speed at 16 weeks
Measurement: 15-feet walking test
Time frame: Baseline and at 16 weeks
Change from baseline in serum myostatin levels at 16 weeks
Measurement: ELISA test
Time frame: Baseline and at 16 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.